

Federal Communications Commission.

**Marlene Dortch,**

*Secretary, Office of the Secretary.*

[FR Doc. 2020-09807 Filed 5-7-20; 8:45 am]

BILLING CODE 6712-01-P

## FEDERAL COMMUNICATIONS COMMISSION

[OMB 3060-1246; FRS 16726]

### Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority

**AGENCY:** Federal Communications Commission.

**ACTION:** Notice and request for comments.

**SUMMARY:** As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act (PRA) of 1995, the Federal Communications Commission (FCC or the Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collection. Comments are requested concerning: Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees. The FCC may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the PRA that does not display a valid Office of Management and Budget (OMB) control number.

**DATES:** Written PRA comments should be submitted on or before July 7, 2020. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

**ADDRESSES:** Direct all PRA comments to Nicole Ongele, FCC, via email [PRA@fcc.gov](mailto:PRA@fcc.gov) and to [Nicole.Ongele@fcc.gov](mailto:Nicole.Ongele@fcc.gov).

**FOR FURTHER INFORMATION CONTACT:** For additional information about the information collection, contact Nicole Ongele at (202) 418-2991.

#### SUPPLEMENTARY INFORMATION:

*OMB Control Number:* 3060-1246.

*Title:* FCC Reasonable Accommodation forms.

*Form Number(s):* FCC Form 5626, FCC Form 5627.

*Type of Review:* Extension of a currently approved collection.

*Respondents:* Individuals or households; Federal Government.

*Number of Respondents and Responses:* 54 respondents; 108 responses.

*Estimated Time per Response:* 0.16 hours-5 hours.

*Frequency of Response:* One-time reporting requirement.

*Obligation to Respond:* Voluntary. Statutory authority for these collections is contained in the Rehabilitation Act of 1973, 29 U.S.C. 12101 *et seq.*; *see also* 29 CFR part 1630; Establishing Procedures to Facilitate the Provision of Reasonable Accommodation; EEOC, Enforcement Guidance on Reasonable Accommodation and Undue Hardship Under the Americans with Disabilities Act, 29 CFR part 1615.

*Total Annual Burden:* 284 hours.

*Total Annual Cost:* \$3,400.

*Privacy Act Impact Assessment:* Yes. The PII in this information collection is covered by the Equal Employment Opportunity Commission's Government-wide System of Records Notice or "SORN," EEOC/GOVT-1, Equal Employment Opportunity in the Federal Government's Complaint and Appeal Records.

*Nature and Extent of Confidentiality:* Confidentiality of information will be provided in accordance with the Privacy Act. The Commission is not requesting respondents to submit confidential information to the Commission. If the Commission requests respondents to submit information which respondents believe is confidential, respondents may request confidential treatment of such information pursuant to section 0.459 of the Commission's rules, 47 CFR 0.459.

*Needs and Uses:* This information will be used by the Office of Workplace Diversity to process, track, and maintain the confidentiality of reasonable accommodation requests submitted on FCC Form 5626 and FCC Form 5627.

Federal Communications Commission.

**Marlene Dortch,**

*Secretary, Office of the Secretary.*

[FR Doc. 2020-09808 Filed 5-7-20; 8:45 am]

BILLING CODE 6712-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Administration for Native Americans; Notice of Meeting

**AGENCY:** Administration for Children and Families, Department of Health and Human Services.

**ACTION:** Notice of Tribal Consultation.

**SUMMARY:** The U.S. Department of Health and Human Services, Administration for Children and Families (ACF) will host a virtual Tribal Consultation to consult on ACF programs and tribal priorities.

#### DATES:

Wednesday, June 10, 2020 from 1:00 p.m. to 5:45 p.m. (EDT) and Thursday, June 11, 2020 from 1:00 p.m. to 5:45 p.m. (EDT)

**ADDRESSES:** Adobe Connect virtual platform and teleconference.

#### FOR FURTHER INFORMATION CONTACT:

Michelle Sauve, Intergovernmental Affairs Specialist, Administration for Native Americans at 202-260-6974, by email at [michelle.sauve@acf.hhs.gov](mailto:michelle.sauve@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The Administration for Children and Families (ACF), a division of the U.S. Department of Health and Human Services (HHS), promotes the economic and social well-being of families, children, individuals and communities with funding, strategic partnerships, guidance, training, and technical assistance. ACF's programs serve a wide variety of groups, including individuals and families with low income, refugees, Native Americans, and many others. To carry out its activities, ACF awards grants to state and local governments, non-profit groups, faith and community-based organizations, federally recognized Indian tribes, and in some programs, state-recognized or other Native American communities. ACF furnishes technical assistance, guidance, and overall supervision to grantees that, in turn, are responsible for direct delivery of services.

Pursuant to Executive Order 13175 of November 6, 2000 and the ACF Tribal Consultation Policy signed in 2011, ACF will host an annual tribal consultation in recognition of the government-to-government relationship between the United States and Indian tribes. Tribes may comment on any program or service of ACF as part of the consultation.

This year, when H.R. 1865, Further Consolidated Appropriations Act, 2020, became Public Law No: 116-94 on

December 20, 2019, the appropriations language encouraged ACF “to convene a working group of federal early childhood program administrators, tribal early childhood stakeholders, and tribal leaders to examine coordination issues that may be impacting early childhood initiatives in tribal communities.” We are interested in tribal leader input on barriers and opportunities regarding synchronizing early childhood initiatives in their communities.

We invite tribes to provide written testimony, in advance, to the Administration for Children and Families to help guide discussion. Testimonies are to be submitted no later than June 10, 2020 to the following: Jeannie Hovland, Commissioner, Administration for Native Americans, [anacommissioner@acf.hhs.gov](mailto:anacommissioner@acf.hhs.gov).

For further information and registration details for this Consultation, please visit the following link: <https://www.acf.hhs.gov/ana/2020-acf-tribal-consultation>.

**Linda K. Hitt,**

*Executive Secretariat Certifying Officer.*

[FR Doc. 2020-09850 Filed 5-7-20; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2018-D-1711]

#### **Cytomegalovirus in Transplantation: Developing Drugs To Treat or Prevent Disease; Final Guidance for Industry; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease.” The purpose of this guidance is to assist sponsors in all phases of the clinical development of drugs and biological products to treat or prevent cytomegalovirus (CMV) disease in patients who have undergone solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). This guidance finalizes the draft guidance of the same name issued on May 21, 2018.

**DATES:** The announcement of the guidance is published in the **Federal Register** on May 8, 2020.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### *Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

*Instructions:* All submissions received must include the Docket No. FDA-2018-D-1711 for “Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper

submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

*Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

**FOR FURTHER INFORMATION CONTACT:** Jeffrey Murray, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6370, Silver Spring, MD 20993-0002, 301-796-1500.

#### **SUPPLEMENTARY INFORMATION:**

##### **I. Background**

FDA is announcing the availability of a final guidance for industry entitled